Innate Pharma (IPHA) Receivables (2017 - 2025)

Innate Pharma has reported Receivables for 9 years, with the latest figure at $15.4 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables changed 0.05% year-over-year to $15.4 million; the trailing twelve-month figure through Dec 2025 stood at $15.4 million (changed 0.05% YoY), and the FY2025 full-year result was $15.4 million, changed 0.05% from the prior year.
• Receivables for Q4 2025 stood at $15.4 million, up from $5.6 million in the prior quarter.
• The five-year high for Receivables was $65.7 million in Q2 2022, with the low at $5.6 million in Q2 2025.
• Historically, Receivables has averaged $40.9 million across 5 years, with a median of $54.0 million in 2021.
• Annual changes were most pronounced in 2021 — Receivables tumbled 99.66% — and 2022, when it climbed 20.83%.
• Innate Pharma's Receivables stood at $56.1 million in 2021, then declined by 4.54% to $53.6 million in 2022, then climbed by 11.8% to $59.9 million in 2023, then slumped by 74.33% to $15.4 million in 2024, then advanced by 0.05% to $15.4 million in 2025.
• The last three Receivables figures came in at $15.4 million (Q4 2025), $5.6 million (Q2 2025), and $15.4 million (Q4 2024), per Business Quant data.